Paper Details

  1. Home
  2. Paper Details

Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study.

Author: BartlettNancy L, ChenAndy I, HaiounCorinne, HirataJamie, KolibabaKathryn, LeeCalvin, LuDan, MehtaAmitkumar, MorschhauserFranck, MunozJavier, PenuelElicia, SallesGilles, SharmanJeff P, TillyHervé, YanMark

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study evaluated the safety and preliminary activity of polatuzumab vedotin, an antibody-drug conjugate targeting the CD79b component of the B-cell receptor, in combination with rituximab or obinutuzumab and cyclophosphamide, doxorubicin, and prednisone (CHP) in patients with previously untreated diffuse large B-cell lymphoma.
Paper Details　
Original Abstract of the Article :
Polatuzumab vedotin, an antibody-drug conjugate targeting the CD79b component of the B-cell receptor, has demonstrated activity as a single agent and in combination with rituximab in relapsed or refractory diffuse large B-cell lymphoma. In this study, we evaluated the safety and preliminary activity...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S1470-2045(19)30091-9

データ提供：米国国立医学図書館（NLM）

Polatuzumab Vedotin in Combination with Immunochemotherapy for Diffuse Large B-Cell Lymphoma

This study investigated the safety and efficacy of polatuzumab vedotin, an antibody-drug conjugate, in combination with immunochemotherapy for the treatment of previously untreated diffuse large B-cell lymphoma. The authors conducted a phase 1b-2 study evaluating the combination of polatuzumab vedotin with either rituximab or obinutuzumab and cyclophosphamide, doxorubicin, and prednisone (CHP) in patients with this aggressive form of lymphoma.

A Potential Breakthrough in Lymphoma Treatment

This study provides encouraging preliminary results, suggesting that the combination of polatuzumab vedotin with immunochemotherapy may be a promising treatment option for patients with previously untreated diffuse large B-cell lymphoma. The findings are like a refreshing spring in the arid landscape of lymphoma research, offering a potential source of hope for those battling this challenging disease.

Navigating the Complexities of Lymphoma Therapy

This study highlights the need for further research to fully evaluate the efficacy and safety of this combination therapy. The authors emphasize the importance of understanding the complex interactions between polatuzumab vedotin, immunochemotherapy, and the underlying biology of diffuse large B-cell lymphoma. This knowledge is crucial for optimizing treatment regimens and improving patient outcomes.

Dr. Camel's Conclusion

This research, like a caravan venturing into the vast desert of lymphoma research, offers a promising new direction. The combination of polatuzumab vedotin with immunochemotherapy holds potential for improving treatment outcomes for patients with diffuse large B-cell lymphoma. While further research is needed, this study provides a glimmer of hope in the ongoing battle against this aggressive form of cancer.
Date :
  1. Date Completed 2020-06-22
  2. Date Revised 2023-01-06
Further Info :

Pubmed ID

31101489

DOI: Digital Object Identifier

10.1016/S1470-2045(19)30091-9

Related Literature

Article Analysis
・Effects of obinutuzumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.